Phase Ia Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) in Patients With Recurrent Advanced Solid Tumors

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-018-0351-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy